Following an August 19 meeting convened by the Forum for Collaborative HIV Research to explore recent findings showing the success of pre-exposure prophylaxis (PrEP), “conference participants urged healthcare providers and the public to await further guidance from the CDC and FDA before considering using PrEP. However, if providers believe that initiating PrEP is urgent for a specific patient, CDC recommends following the cautions and procedures previously published for PrEP use in MSM” (men who have sex with men), a Forum press release states. The release outlines other considerations undertaken by the meeting participants (8/24).